Cormorant Asset Management has fully liquidated its position in Arcellx (ACLX), selling 775,000 shares for approximately $63.63 million, as disclosed in a recent SEC filing. This move eliminates Cormorant’s stake, which previously accounted for 4.4% of its 13F reportable assets under management, highlighting a significant shift in its investment strategy.

The timing of this sale is notable, as Arcellx shares have surged 80% this year, driven by strong clinical responses from its lead CAR-T cell therapy for multiple myeloma. The recent takeover agreement with Gilead Sciences, valuing Arcellx at around $7.8 billion, underscores the growing interest from larger pharmaceutical companies in innovative oncology treatments. This development not only reflects the potential for substantial returns in the biotech sector but also serves as a reminder of the importance of timing in investment decisions.

For a deeper dive into the implications of Cormorant’s exit and Arcellx’s market trajectory, I recommend checking out the full article.

Source: fool.com